您的购物车当前为空
Trevogrumab(REGN-1033) 是一种全人源单克隆抗体,特异性靶向并抑制生长分化因子8(GDF8,亦称肌生长抑制素)的活性,GDF8是肌肉生长的负向调节因子。Trevogrumab 目前正被广泛研究用于肌少症,一种以持续性的、广泛性骨骼肌质量与功能丧失为特征的复杂病症。
别名 曲戈卢单抗, REGN-1033, REGN1033
Trevogrumab(REGN-1033) 是一种全人源单克隆抗体,特异性靶向并抑制生长分化因子8(GDF8,亦称肌生长抑制素)的活性,GDF8是肌肉生长的负向调节因子。Trevogrumab 目前正被广泛研究用于肌少症,一种以持续性的、广泛性骨骼肌质量与功能丧失为特征的复杂病症。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 2,650 | 现货 | |
| 5 mg | ¥ 6,150 | 现货 | |
| 10 mg | ¥ 8,280 | 现货 | |
| 25 mg | ¥ 12,300 | 现货 | |
| 50 mg | ¥ 16,500 | 现货 |
TargetMol的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。
| 产品描述 | Trevogrumab (REGN-1033) is a fully human monoclonal antibody specifically designed to target and inhibit the activity of growth differentiation factor 8 (GDF8), which is also known as myostatin and functions as a negative regulator of muscle growth;Trevogrumab is currently under extensive research of sarcopenia, a complex condition characterized by progressive and generalized loss of skeletal muscle mass and function often associated with aging, wasting atrophy, various chronic diseases, and significant alterations in dietary and nutritional intake. |
| 体外活性 | Trevogrumab (40nM,30分钟)处理人类骨骼成肌细胞,WesternBlot检测目标蛋白的水平变化。 |
| 体内活性 | Trevogrumab (0.1-30 mg/kg,皮下注射 ,每周两次,持续 4 周处理小鼠,结果小鼠腓肠肌 (GA) 和胫骨前肌 (TA) 肌肉重量显着增加 (~20%),小鼠肌纤维面积增加 (~15%)。[1] |
| 别名 | 曲戈卢单抗, REGN-1033, REGN1033 |
| 反应种属 | Human |
| 应用 | ELISAFCMFunctional assay |
| 抗体种类 | Monoclonal |
| 缓冲液 | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| 内毒素 | <1.0 EU/mg |
| 同型 | Human IgG4 kappa |
| 推荐同型对照 |
| 偶联 | Unconjugated |
| 基因ID | |
| Uniprot ID | |
| 靶点 | GDF8/Myostatin |
| 分子量 | 144.02 kDa |
| CAS No. | 1429201-24-0 |
| 存储 | -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature. 实际储存温度请以COA为准 |
对于不同动物的给药剂量换算,您也可以参考 更多